Want to see TSE:RVX full AI Analyst Report?
Top Page
Resverlogix
(TSX:RVX)
Select Model
Select Model
Rating:43Neutral
Price Target:
C$0.09
▼(-8.00% Downside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and a highly leveraged, negative-equity balance sheet). Technical indicators are relatively neutral and provide only limited offset, while valuation is constrained by a negative P/E and no dividend yield support.
Positive Factors
Platform & Science
Resverlogix’s focus on epigenetic mechanisms, notably BET proteins, is a durable scientific differentiator. A platform approach can enable multiple programs and indication expansions, improving long-term partnership appeal and increasing optionality for licensing or co-development deals.
Negative Factors
No Revenue, Large Losses
The company reports no revenue across recent periods while incurring sizable operating and net losses. This structural lack of operating income means ongoing R&D investments must be funded externally, leaving execution and survival dependent on successful financing or deals.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform & Science
Resverlogix’s focus on epigenetic mechanisms, notably BET proteins, is a durable scientific differentiator. A platform approach can enable multiple programs and indication expansions, improving long-term partnership appeal and increasing optionality for licensing or co-development deals.
Read all positive factors
Resverlogix (RVX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$34.39M
Dividend YieldN/A
Average Volume (3M)37.18K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue GrowthN/A
EPS Growth58.17%
CountryCA
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding343,916,100
10 Day Avg. Volume62,041
30 Day Avg. Volume37,183
Financial Highlights & Ratios
PEG Ratio-7.26
Price to Book (P/B)-0.23
Price to Sales (P/S)0.00
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Resverlogix Business Overview & Revenue Model
Company Description
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabeta...
How the Company Makes Money
Resverlogix’s business model is primarily that of a clinical-stage biopharmaceutical developer. As a result, revenue (when present) typically comes from partnering and financing activities rather than recurring product sales. Key potential money s...
Resverlogix Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2022 | Mar 2022 | Jul 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -437.53K | -476.75K | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.77M | -4.25M | -11.74M | -14.87M | ― |
| Net Income | -7.90M | -7.63M | -3.61M | -24.77M | ― |
Balance Sheet | |||||
| Total Assets | 7.93M | 7.34M | 8.12M | 9.98M | 10.71K |
| Cash, Cash Equivalents and Short-Term Investments | 107.80K | 99.00K | 40.00K | 6.00K | 87.00 |
| Total Debt | 72.77M | 81.97M | 6.49M | 7.04M | 0.00 |
| Total Liabilities | 96.73M | 89.08M | 67.40M | 69.85M | 50.60K |
| Stockholders Equity | -88.80M | -81.73M | -59.28M | -59.87M | -94.90K |
Cash Flow | |||||
| Free Cash Flow | -3.73M | -4.36M | -3.99M | -8.90M | -4.41K |
| Operating Cash Flow | -3.73M | -3.89M | -3.54M | -8.02M | -4.40K |
| Investing Cash Flow | -660.36K | -377.00K | -473.00K | -833.00K | -426.00 |
| Financing Cash Flow | 4.39M | 4.36M | 4.06M | 8.81M | 4.95K |
Resverlogix Technical Analysis
Positive
0.10
Price Trends
0.10
Positive
0.10
Negative
0.10
Negative
Market Momentum
<0.01
Positive
53.90
Neutral
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVX, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.90 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:RVX.
Resverlogix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | C$41.25M | -7.56 | -21.02% | ― | -34.81% | -453.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$41.06M | -0.28 | -147.92% | ― | ― | 85.31% | |
45 Neutral | C$5.09M | -0.20 | -135.33% | ― | ― | -79.26% | |
43 Neutral | C$34.39M | -2.70 | 6.67% | ― | ― | 58.17% |
* Healthcare Sector Average
TSE:RVX
Resverlogix
0.10
-0.02
-13.04%
TSE:XRTX
XORTX Therapeutics Inc
2.80
-3.20
-53.33%
TSE:BCT
BriaCell Therapeutics
4.74
-5.16
-52.12%
TSE:MBX
Microbix Biosystms
0.32
0.04
14.29%
TSE:GSD
Devonian Health Group
7.75
-0.05
-0.63%
TSE:TTI
Thiogenesis Therapeutics Corp
0.56
-0.22
-28.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.